Business
Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Reported positive topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) - - THRIVE Phase 3 trial in
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"\n- Reported positive topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) -\n\n\n- THRIVE Phase 3 trial in patients with active TED amended to reflect Viridian’s confidence in 5-infusion treatment regimen and key stakeholder feedback on evolving TED treatment paradigm –\n\n\n- THRIVE-2 Phase 3 trial in patients with chronic TED expected to start in the third quarter of 2023 –\n\n\n- Selection of lead subcutaneous (SC) program in TED planned for year-end 2023 -\n\n\n WALTHAM, Mass.--(BUSINESS WIRE)--\nViridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the second quarter ended June 30, 2023.\n\n\n“Last month, we established proof-of-concept for VRDN-001 in patients with chronic TED, marking an exciting milestone for the Company and building on the compelling data we previously reported in active TED. VRDN-001 demonstrated profound clinical activity in chronic TED patients after only two infusions, confirming this candidate’s ability to potentially be an effective therapy in active and chronic TED,” said Scott Myers, President and CEO of Viridian Therapeutics. “We are also quickly advancing our potential first-in-class subcutaneous TED program and are proud to announce that our Phase 1 trial for VRDN-001 SC in healthy volunteers is fully enrolled. In addition, our Phase 1 trial for VRDN-003 SC has been initiated and is now enrolling healthy volunteers.”\n\n\nAdded Mr. Myers: “The significant strides we have made with our TED program this quarter lay the foundation for us to execute on all upcoming key milestones. We remain committed to initiating our Phase 3 THRIVE-2 trial of VRDN-001 in chronic TED patients during the third quarter – our second pivotal trial for this candidate – and selecting our lead subcutaneous program by year-end.”\n\n\nProgram highlights\n\n\nThyroid eye disease (TED)\n\n\nIntravenous (IV) program: VRDN-001\n\n\nViridian’s lead product candidate, VRDN-001, is a monoclonal antibody which acts as a full antagonist of insulin-like growth factor-1 receptor (IGF-1R). VRDN-001 is being evaluated in clinical trials for the treatment of active and chronic TED.\n\n\n\nPreliminary ...